We have located links that may give you full text access.
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Presentation, Diagnosis, and Management.
Pediatric Annals 2021 June
Pediatric demyelinating syndromes are a spectrum of diseases affecting the central nervous system. In the past decade, major advances have been made in this field, including the discovery of antibody-based biomarkers and treatment guidelines for specific syndromes. When myelin oligodendrocyte glycoprotein (MOG) antibodies were first discovered, they were thought to be a biomarker for multiple sclerosis (MS). However, further research has shown that MOG positivity during the first episode of a pediatric demyelinating syndrome is a predictor of a course that is distinct to MS. This article discusses the clinical manifestations of MOG antibody associated disease and key distinguishing features in the investigation, treatment, and prognosis between MOG and other demyelinating diseases. [ Pediatr Ann . 2021;50(6):e254-e258.] .
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app